Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds
Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds
For additional information, visit the Company's website, . Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock.
马尔伯勒，马萨诸塞州-（新闻稿发布 corp. - 2024年7月5日）-Phio Pharmaceuticals corp.（纳斯达克股票代码：PHIO），一家临床阶段的生物技术公司，其专有的INTASYL siRNA基因沉默技术旨在使免疫细胞更有效地杀灭肿瘤细胞，今天宣布已终止其与Triton Funds LP的股份购买协议，该协议为Triton提供了购买公司普通股的机会，最高可买入18.8％。
About Phio Pharmaceuticals Corp.
关于Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Phio Pharmaceuticals Corp. (纳斯达克:PHIO)是一家临床阶段的生物技术公司，其专有INTASYL siRNA基因沉默技术旨在使免疫细胞在杀死肿瘤细胞方面更加有效。INTASYL是唯一专注于免疫学肿瘤治疗领域的自释放RNAi技术。INTASYL药物精确地针对特定蛋白质，降低了身体对癌症的抵抗能力，而不需要专门的配方或药物输送系统。
For additional information, visit the Company's website, .
有关更多信息，请访问公司网站。
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
联系方式：
Phio Pharmaceuticals Corp.
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
PR联系人
迈克尔·亚当斯
Bridge View Media
adams@bridgeviewmedia.com
To view the source version of this press release, please visit
要查看此新闻发布的源版本，请访问